Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paricalcitol Oral Solution for Secondary Hyperparathyroidism in Pediatric Subjects With Stage 5 CKD
NCT04064827Phase 3Terminated
- Sponsor
- AbbVie Inc.
- Start
- Sep 2020
- Primary completion
- Jun 2025
- Countries
- 2
01
Overview
A Phase 3 trial of paricalcitol oral solution in secondary hyperparathyroidism (SHPT), sponsored by AbbVie Inc.. Started Sep 2020; status: terminated.
02
Drugs
paricalcitol oral solution
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT04064827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04064827.